171 related articles for article (PubMed ID: 22509395)
21. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses.
Kim D; Monie A; He L; Tsai YC; Hung CF; Wu TC
Gene Ther; 2008 May; 15(9):677-87. PubMed ID: 18273057
[TBL] [Abstract][Full Text] [Related]
22. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
Zhang T; Sentman CL
J Immunol; 2013 Mar; 190(5):2455-63. PubMed ID: 23355740
[TBL] [Abstract][Full Text] [Related]
23. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X; Li CR; Yang J; Wang GB
Scand J Immunol; 2013 May; 77(5):389-97. PubMed ID: 23298273
[TBL] [Abstract][Full Text] [Related]
24. A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response.
Kim TW; Hung CF; Zheng M; Boyd DA; He L; Pai SI; Wu TC
J Biomed Sci; 2004; 11(4):493-9. PubMed ID: 15153784
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
[TBL] [Abstract][Full Text] [Related]
26. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells.
Burgess SJ; Marusina AI; Pathmanathan I; Borrego F; Coligan JE
J Immunol; 2006 Feb; 176(3):1490-7. PubMed ID: 16424177
[TBL] [Abstract][Full Text] [Related]
27. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity.
Lin CT; Tsai YC; He L; Yeh CN; Chang TC; Soong YK; Monie A; Hung CF; Lai CH
Immunol Lett; 2007 Dec; 114(2):86-93. PubMed ID: 17976741
[TBL] [Abstract][Full Text] [Related]
28. NKG2D defines tumor-reacting effector CD8
Mojic M; Shitaoka K; Ohshima C; Ucche S; Lyu F; Hamana H; Tahara H; Kishi H; Hayakawa Y
Cancer Sci; 2021 Sep; 112(9):3484-3490. PubMed ID: 34187084
[TBL] [Abstract][Full Text] [Related]
29. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.
Best SR; Peng S; Juang CM; Hung CF; Hannaman D; Saunders JR; Wu TC; Pai SI
Vaccine; 2009 Sep; 27(40):5450-9. PubMed ID: 19622402
[TBL] [Abstract][Full Text] [Related]
30. NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase.
Wensveen FM; Lenartic M; Jelencic V; Lemmermann NA; ten Brinke A; Jonjic S; Polic B
J Immunol; 2013 Aug; 191(3):1307-15. PubMed ID: 23804716
[TBL] [Abstract][Full Text] [Related]
31. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
32. Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis.
Jiang G; Ng YY; Tay JCK; Du Z; Xiao L; Wang S; Zhu J
Cancer Immunol Immunother; 2023 Jan; 72(1):223-234. PubMed ID: 35809118
[TBL] [Abstract][Full Text] [Related]
33. Negative regulation of NKG2D expression by IL-4 in memory CD8 T cells.
Ventre E; Brinza L; Schicklin S; Mafille J; Coupet CA; Marçais A; Djebali S; Jubin V; Walzer T; Marvel J
J Immunol; 2012 Oct; 189(7):3480-9. PubMed ID: 22942430
[TBL] [Abstract][Full Text] [Related]
34. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.
Groh V; Wu J; Yee C; Spies T
Nature; 2002 Oct; 419(6908):734-8. PubMed ID: 12384702
[TBL] [Abstract][Full Text] [Related]
35. Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells.
Conejo-Garcia JR; Benencia F; Courreges MC; Khang E; Zhang L; Mohamed-Hadley A; Vinocur JM; Buckanovich RJ; Thompson CB; Levine B; Coukos G
Cancer Biol Ther; 2003; 2(4):446-51. PubMed ID: 14508119
[TBL] [Abstract][Full Text] [Related]
36. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
[TBL] [Abstract][Full Text] [Related]
37. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.
Tseng CW; Trimble C; Zeng Q; Monie A; Alvarez RD; Huh WK; Hoory T; Wang MC; Hung CF; Wu TC
Cancer Immunol Immunother; 2009 May; 58(5):737-48. PubMed ID: 18815785
[TBL] [Abstract][Full Text] [Related]
38. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
Cerboni C; Ardolino M; Santoni A; Zingoni A
Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
[TBL] [Abstract][Full Text] [Related]
39. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
Karimi M; Cao TM; Baker JA; Verneris MR; Soares L; Negrin RS
J Immunol; 2005 Dec; 175(12):7819-28. PubMed ID: 16339517
[TBL] [Abstract][Full Text] [Related]
40. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells.
Fernández-Sánchez A; Baragaño Raneros A; Carvajal Palao R; Sanz AB; Ortiz A; Ortega F; Suárez-Álvarez B; López-Larrea C
Epigenetics; 2013 Jan; 8(1):66-78. PubMed ID: 23235109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]